image
Healthcare - Medical - Devices - NASDAQ - GB
$ 48.3
0.667 %
$ 2.62 B
Market Cap
112.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one LIVN stock under the worst case scenario is HIDDEN Compared to the current market price of 48.3 USD, LivaNova PLC is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one LIVN stock under the base case scenario is HIDDEN Compared to the current market price of 48.3 USD, LivaNova PLC is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one LIVN stock under the best case scenario is HIDDEN Compared to the current market price of 48.3 USD, LivaNova PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
1.15 B REVENUE
12.89%
-68.5 M OPERATING INCOME
-129.98%
17.5 M NET INCOME
120.35%
74.9 M OPERATING CASH FLOW
7.17%
-40.3 M INVESTING CASH FLOW
-5.03%
21.5 M FINANCING CASH FLOW
-92.33%
318 M REVENUE
-0.14%
35.6 M OPERATING INCOME
-23.42%
33 M NET INCOME
101.76%
51 M OPERATING CASH FLOW
17.62%
-18.5 M INVESTING CASH FLOW
-47.35%
-3.28 M FINANCING CASH FLOW
72.35%
Balance Sheet LivaNova PLC
image
Current Assets 988 M
Cash & Short-Term Investments 267 M
Receivables 215 M
Other Current Assets 507 M
Non-Current Assets 1.44 B
Long-Term Investments 22.8 M
PP&E 205 M
Other Non-Current Assets 1.21 B
Current Liabilities 335 M
Accounts Payable 80.8 M
Short-Term Debt 26.5 M
Other Current Liabilities 228 M
Non-Current Liabilities 817 M
Long-Term Debt 614 M
Other Non-Current Liabilities 203 M
EFFICIENCY
Earnings Waterfall LivaNova PLC
image
Revenue 1.15 B
Cost Of Revenue 382 M
Gross Profit 771 M
Operating Expenses 844 M
Operating Income -68.5 M
Other Expenses -86 M
Net Income 17.5 M
RATIOS
66.86% GROSS MARGIN
66.86%
-5.94% OPERATING MARGIN
-5.94%
1.52% NET MARGIN
1.52%
1.37% ROE
1.37%
0.72% ROA
0.72%
0.80% ROIC
0.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis LivaNova PLC
image
Net Income 17.5 M
Depreciation & Amortization 60.9 M
Capital Expenditures -35 M
Stock-Based Compensation 36.4 M
Change in Working Capital -34.6 M
Others 113 M
Free Cash Flow 39.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets LivaNova PLC
image
Wall Street analysts predict an average 1-year price target for LIVN of $68 , with forecasts ranging from a low of $65 to a high of $72 .
LIVN Lowest Price Target Wall Street Target
65 USD 34.58%
LIVN Average Price Target Wall Street Target
68 USD 40.79%
LIVN Highest Price Target Wall Street Target
72 USD 49.07%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership LivaNova PLC
image
Sold
0-3 MONTHS
63.7 K USD 1
3-6 MONTHS
69.9 K USD 1
6-9 MONTHS
3.4 M USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Dec 11, 2024
Sell 63.7 K USD
Bianchi Francesco
Director
- 1250
50.99 USD
4 months ago
Sep 11, 2024
Sell 69.9 K USD
Bianchi Francesco
Director
- 1500
46.58 USD
7 months ago
Jun 03, 2024
Sell 3.28 M USD
Moore Daniel Jeffrey
Director
- 54578
60.075 USD
7 months ago
Jun 03, 2024
Sell 125 K USD
Moore Daniel Jeffrey
Director
- 2045
61.086 USD
1 year ago
Mar 30, 2023
Sell 94.5 K USD
McDonald Damien
CEO
- 2220
42.55 USD
2 years ago
Dec 15, 2022
Sell 121 K USD
McDonald Damien
CEO
- 2220
54.56 USD
2 years ago
Apr 01, 2022
Sell 83.4 K USD
Moore Daniel Jeffrey
director:
- 1000
83.416 USD
2 years ago
Mar 29, 2022
Sell 227 K USD
McDonald Damien
CEO
- 2784
81.5 USD
2 years ago
Mar 02, 2022
Sell 80 K USD
Moore Daniel Jeffrey
director:
- 1000
80 USD
2 years ago
Feb 25, 2022
Sell 80 K USD
Moore Daniel Jeffrey
Director
- 1000
80 USD
3 years ago
Jan 03, 2022
Sell 85.9 K USD
Moore Daniel Jeffrey
Director
- 1000
85.9341 USD
3 years ago
Dec 13, 2021
Sell 227 K USD
McDonald Damien
CEO
- 2784
81.5 USD
3 years ago
Dec 01, 2021
Sell 81.7 K USD
Moore Daniel Jeffrey
Director
- 1000
81.734 USD
3 years ago
Nov 10, 2021
Sell 58.5 K USD
Novak Alfred J
Director
- 644
90.7659 USD
3 years ago
Nov 11, 2021
Sell 208 K USD
Novak Alfred J
Director
- 2337
89.1729 USD
3 years ago
Nov 10, 2021
Bought 90.4 K USD
KOZY WILLIAM A
Director
+ 1000
90.4282 USD
3 years ago
Nov 03, 2021
Sell 85.2 K USD
Moore Daniel Jeffrey
Director
- 1000
85.25 USD
3 years ago
Oct 01, 2021
Sell 80 K USD
Moore Daniel Jeffrey
Director
- 1000
80 USD
3 years ago
Sep 01, 2021
Sell 82.4 K USD
Moore Daniel Jeffrey
Director
- 1000
82.4015 USD
3 years ago
Aug 02, 2021
Sell 86.4 K USD
Moore Daniel Jeffrey
Director
- 1000
86.3886 USD
3 years ago
Jun 29, 2021
Sell 84.2 K USD
Moore Daniel Jeffrey
Director
- 1000
84.2 USD
3 years ago
May 18, 2021
Sell 602 K USD
Dolci Marco
SVP Global Operations, R&D
- 7259
82.8654 USD
3 years ago
May 18, 2021
Sell 84.8 K USD
Dolci Marco
SVP Global Operations, R&D
- 1019
83.2259 USD
4 years ago
Jun 16, 2020
Bought 46.7 K USD
Novak Alfred J
Director
+ 1000
46.713 USD
4 years ago
Feb 03, 2020
Sell 68 K USD
McDonald Damien
CEO
- 1000
68 USD
5 years ago
Jan 02, 2020
Sell 75.7 K USD
McDonald Damien
CEO
- 1000
75.68 USD
5 years ago
Dec 02, 2019
Sell 83.7 K USD
McDonald Damien
CEO
- 1000
83.71 USD
5 years ago
Nov 22, 2019
Sell 240 K USD
Moore Daniel Jeffrey
Director
- 3000
80 USD
5 years ago
Nov 01, 2019
Sell 74.4 K USD
McDonald Damien
CEO
- 1000
74.4 USD
5 years ago
Oct 01, 2019
Sell 73.8 K USD
McDonald Damien
CEO
- 1000
73.82 USD
5 years ago
Sep 16, 2019
Sell 127 K USD
Moore Daniel Jeffrey
Director
- 1500
84.5635 USD
5 years ago
Sep 03, 2019
Sell 77 K USD
McDonald Damien
CEO
- 1000
77 USD
5 years ago
Aug 19, 2019
Sell 120 K USD
Moore Daniel Jeffrey
Director
- 1500
80.25 USD
5 years ago
Aug 12, 2019
Sell 163 K USD
Huston Thad Allen
Chief Financial Officer
- 2000
81.49 USD
5 years ago
Aug 01, 2019
Sell 480 K USD
Moore Daniel Jeffrey
Director
- 6000
80 USD
5 years ago
Aug 01, 2019
Sell 77.5 K USD
McDonald Damien
CEO
- 1000
77.53 USD
5 years ago
Jul 01, 2019
Sell 72.6 K USD
McDonald Damien
CEO
- 1000
72.6 USD
5 years ago
Jun 20, 2019
Sell 150 K USD
Huston Thad Allen
Chief Financial Officer
- 2000
75 USD
5 years ago
Jun 05, 2019
Sell 73.6 K USD
McDonald Damien
CEO
- 1000
73.58 USD
5 years ago
May 09, 2019
Sell 91.8 K USD
Novak Alfred J
Director
- 1300
70.6322 USD
5 years ago
May 02, 2019
Bought 72.8 K USD
KOZY WILLIAM A
Director
+ 1000
72.806 USD
5 years ago
Mar 15, 2019
Sell 145 K USD
Moore Daniel Jeffrey
Director
- 1500
96.6293 USD
5 years ago
Feb 15, 2019
Sell 151 K USD
Moore Daniel Jeffrey
Director
- 1500
100.4402 USD
6 years ago
Jan 15, 2019
Sell 136 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
90.9111 USD
6 years ago
Jan 15, 2019
Sell 136 K USD
Moore Daniel Jeffrey
Director
- 1500
90.8 USD
6 years ago
Jan 10, 2019
Sell 40.5 K USD
Simpson Alistair
General Manager, CS
- 450
90.1 USD
6 years ago
Dec 15, 2018
Sell 91.8 K USD
Moore Daniel Jeffrey
Director
- 1000
91.846 USD
6 years ago
Dec 17, 2018
Sell 138 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
92.12 USD
6 years ago
Dec 11, 2018
Sell 48.6 K USD
Novak Alfred J
Director
- 500
97.1601 USD
6 years ago
Nov 15, 2018
Sell 117 K USD
Moore Daniel Jeffrey
Director
- 1000
116.675 USD
6 years ago
Nov 15, 2018
Sell 179 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
119.2347 USD
6 years ago
Nov 05, 2018
Sell 116 K USD
MORRISON HUGH M
Director
- 1000
115.6501 USD
6 years ago
Oct 15, 2018
Sell 169 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
112.8335 USD
6 years ago
Oct 15, 2018
Sell 113 K USD
Moore Daniel Jeffrey
Director
- 1000
113.2977 USD
6 years ago
Sep 17, 2018
Sell 185 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
123.433 USD
6 years ago
Sep 17, 2018
Sell 123 K USD
Moore Daniel Jeffrey
Director
- 1000
123.4877 USD
6 years ago
Aug 15, 2018
Sell 182 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
121.6241 USD
6 years ago
Aug 15, 2018
Sell 250 K USD
Manko Douglas John
Chief Accounting Officer
- 2058
121.6116 USD
6 years ago
Aug 15, 2018
Sell 122 K USD
Moore Daniel Jeffrey
Director
- 1000
121.579 USD
6 years ago
Jul 16, 2018
Sell 153 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
102.0419 USD
6 years ago
Jul 16, 2018
Sell 102 K USD
Moore Daniel Jeffrey
Director
- 1000
102.191 USD
6 years ago
Jun 15, 2018
Sell 105 K USD
Moore Daniel Jeffrey
Director
- 1000
104.95 USD
6 years ago
Jun 15, 2018
Sell 157 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
104.4647 USD
6 years ago
Jun 14, 2018
Sell 104 K USD
Novak Alfred J
Director
- 1000
104.431 USD
6 years ago
Jun 08, 2018
Sell 97 K USD
MORRISON HUGH M
Director
- 1000
97.0132 USD
6 years ago
Jun 08, 2018
Sell 1.52 M USD
McDonald Damien
CEO
- 15742
96.5075 USD
6 years ago
May 31, 2018
Sell 1 M USD
McDonald Damien
CEO
- 11136
89.9 USD
6 years ago
May 23, 2018
Sell 153 K USD
Bianchi Francesco
Director
- 1830
83.8131 USD
6 years ago
May 15, 2018
Sell 127 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
84.4788 USD
6 years ago
May 15, 2018
Sell 84.7 K USD
Moore Daniel Jeffrey
Director
- 1000
84.66 USD
6 years ago
May 09, 2018
Sell 84 K USD
Novak Alfred J
Director
- 1000
84.0164 USD
6 years ago
Apr 16, 2018
Sell 130 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
86.8147 USD
6 years ago
Apr 16, 2018
Sell 86.2 K USD
Moore Daniel Jeffrey
Director
- 1000
86.24 USD
6 years ago
Mar 15, 2018
Sell 88.3 K USD
Moore Daniel Jeffrey
Director
- 1000
88.308 USD
6 years ago
Mar 15, 2018
Sell 132 K USD
WISE DAVID S
Chief Administrative Officer
- 1500
88.1653 USD
6 years ago
Feb 15, 2018
Sell 83.3 K USD
Moore Daniel Jeffrey
Director
- 1000
83.323 USD
7 years ago
Jan 16, 2018
Sell 82.2 K USD
Moore Daniel Jeffrey
Director
- 1000
82.15 USD
7 years ago
Dec 15, 2017
Sell 80.8 K USD
Moore Daniel Jeffrey
Director
- 1000
80.8 USD
7 years ago
Nov 29, 2017
Sell 161 K USD
MORRISON HUGH M
Director
- 1830
88 USD
7 years ago
Nov 22, 2017
Sell 172 K USD
Novak Alfred J
Director
- 2000
85.7693 USD
7 years ago
Nov 15, 2017
Sell 81.4 K USD
Moore Daniel Jeffrey
Director
- 1000
81.39 USD
7 years ago
Oct 16, 2017
Sell 74.6 K USD
Moore Daniel Jeffrey
Director
- 1000
74.5838 USD
7 years ago
Sep 15, 2017
Sell 68.6 K USD
Moore Daniel Jeffrey
Director
- 1000
68.552 USD
7 years ago
Aug 15, 2017
Sell 60.8 K USD
Moore Daniel Jeffrey
Director
- 1000
60.756 USD
7 years ago
Jul 17, 2017
Sell 61.6 K USD
Moore Daniel Jeffrey
Director
- 1000
61.551 USD
7 years ago
Jun 15, 2017
Sell 60.8 K USD
Moore Daniel Jeffrey
Director
- 1000
60.804 USD
7 years ago
May 23, 2017
Bought 58.6 K USD
O'Kane Sharon
Director
+ 1000
58.5806 USD
7 years ago
May 22, 2017
Sell 58.5 K USD
Novak Alfred J
Director
- 1000
58.4868 USD
7 years ago
May 15, 2017
Sell 57.1 K USD
Moore Daniel Jeffrey
Director
- 1000
57.0555 USD
7 years ago
May 05, 2017
Sell 180 K USD
MORRISON HUGH M
Director
- 3215
55.8858 USD
7 years ago
Apr 17, 2017
Sell 51.3 K USD
Moore Daniel Jeffrey
Director
- 1000
51.3159 USD
7 years ago
Mar 15, 2017
Sell 50.2 K USD
Moore Daniel Jeffrey
Director
- 1000
50.205 USD
7 years ago
Feb 21, 2017
Sell 100 K USD
Moore Daniel Jeffrey
Director
- 2000
50 USD
8 years ago
Sep 21, 2016
Sell 5.22 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 85000
61.387 USD
8 years ago
Sep 22, 2016
Sell 1.01 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 16463
61.4291 USD
8 years ago
Sep 22, 2016
Sell 5.16 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 83537
61.7187 USD
8 years ago
Sep 19, 2016
Sell 8.53 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 141301
60.3528 USD
8 years ago
Sep 19, 2016
Sell 4.74 K USD
EQUINOX TWO S.C.A.
10 percent owner
- 78
60.81 USD
8 years ago
Sep 20, 2016
Sell 3.35 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 55394
60.4109 USD
8 years ago
Sep 20, 2016
Sell 4.86 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 79606
61.0225 USD
8 years ago
Sep 21, 2016
Sell 5.23 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 85915
60.9012 USD
8 years ago
Sep 21, 2016
Sell 1.78 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 29085
61.2925 USD
8 years ago
Sep 14, 2016
Sell 241 K USD
EQUINOX TWO S.C.A.
10 percent owner
- 4022
59.9718 USD
8 years ago
Sep 16, 2016
Sell 4.26 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 71191
59.8565 USD
8 years ago
Sep 09, 2016
Sell 366 K USD
EQUINOX TWO S.C.A.
10 percent owner
- 6100
60.0394 USD
8 years ago
Sep 12, 2016
Sell 72 K USD
EQUINOX TWO S.C.A.
10 percent owner
- 1200
60.0108 USD
8 years ago
Sep 13, 2016
Sell 1.09 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 18108
60.0121 USD
8 years ago
Sep 06, 2016
Sell 6.05 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 100000
60.5318 USD
8 years ago
Sep 07, 2016
Sell 3.73 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 61800
60.4294 USD
8 years ago
Sep 07, 2016
Sell 196 K USD
EQUINOX TWO S.C.A.
10 percent owner
- 3200
61.148 USD
8 years ago
Sep 08, 2016
Sell 2.61 M USD
EQUINOX TWO S.C.A.
10 percent owner
- 43000
60.5834 USD
8 years ago
Aug 09, 2016
Sell 242 K USD
Gutedel Jacques
President Intercontinental
- 4000
60.524 USD
8 years ago
May 23, 2016
Sell 15 K USD
Moore Daniel Jeffrey
Director
- 300
50.0733 USD
8 years ago
May 24, 2016
Sell 35 K USD
Moore Daniel Jeffrey
Director
- 700
50.0636 USD
8 years ago
May 19, 2016
Sell 173 K USD
MORRISON HUGH M
Director
- 3600
48 USD
8 years ago
May 06, 2016
Sell 204 K USD
Novak Alfred J
Director
- 4000
51.1227 USD
8 years ago
Apr 15, 2016
Sell 54.8 K USD
Moore Daniel Jeffrey
Director
- 1000
54.8076 USD
8 years ago
Mar 15, 2016
Sell 56.9 K USD
Moore Daniel Jeffrey
Director
- 1000
56.877 USD
8 years ago
Feb 16, 2016
Sell 56.9 K USD
Moore Daniel Jeffrey
Director
- 1000
56.876 USD
9 years ago
Jan 15, 2016
Sell 52.6 K USD
Moore Daniel Jeffrey
Director
- 1000
52.64 USD
9 years ago
Dec 15, 2015
Sell 135 K USD
Moore Daniel Jeffrey
Director
- 2500
53.9692 USD
9 years ago
Nov 16, 2015
Sell 140 K USD
Moore Daniel Jeffrey
Director
- 2500
56.0825 USD
7. News
5 Beaten-Down MedTech Stocks Set to Rebound in 2025 Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape. zacks.com - 2 weeks ago
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. businesswire.com - 1 month ago
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles. businesswire.com - 1 month ago
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. zacks.com - 2 months ago
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. businesswire.com - 2 months ago
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock? LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 2 months ago
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2% The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 2 months ago
Best Momentum Stocks to Buy for November 7th KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024. zacks.com - 2 months ago
New Strong Buy Stocks for November 7th MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024. zacks.com - 2 months ago
Best Value Stocks to Buy for November 7th JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024. zacks.com - 2 months ago
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today. seekingalpha.com - 2 months ago
8. Profile Summary

LivaNova PLC LIVN

image
COUNTRY GB
INDUSTRY Medical - Devices
MARKET CAP $ 2.62 B
Dividend Yield 0.00%
Description LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Contact 20 Eastbourne Terrace, London, W2 6LG https://www.livanova.com
IPO Date Oct. 19, 2015
Employees 2900
Officers Mr. Alex Shvartsburg C.M.A. Chief Financial Officer Mr. Michael D. Hutchinson Senior Vice President, Chief Legal Officer & Company Secretary Mr. Vladimir A. Makatsaria Chief Executive Officer & Director Mr. Paul R. Buckman President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement Ms. Lindsey Little Senior Director of Investor Relations Deanna Wilke Vice President of Corporate Communications Mr. Philip Kowalczyk Chief Strategy & Corporate Development Officer Ms. Stephanie Bolton President of Global Epilepsy Ahmet Tezel Ph.D. Chief Innovation Officer Mr. Franco Poletti President of Cardiopulmonary Business Unit